Literature DB >> 21468550

microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells.

Jun Tao1, Qiang Lu, Deyao Wu, Pengchao Li, Bin Xu, Weijie Qing, Meilin Wang, Zhengdong Zhang, Wei Zhang.   

Abstract

Transitional cell carcinomas (TCCs) of the urinary bladder are common malignancies with a high recurrence rate. Since microRNA-21 (miR-21) may contribute to tumorigenesis and chemoresistance in many cancer types, we aimed to investigate its efficacy in TCCs. The expression of miR-21 and its target PTEN was determined by real-time qRT-PCR and western blotting, respectively in tumor tissues as well as adjacent non-tumor mucosa. The effect of miR-21 on cell proliferation and chemosensitivity to doxorubicin were measured using the MTT method. Cell apoptosis induced by doxorubicin was investigated using flow cytometry in the T24 cell line. BCL-2, AKT and pAKT were detected by western blotting for analysis of potential mechanisms. miR-21 was significantly up-regulated in tumor tissues while PTEN was expressed in lower levels compared to non-tumor tissues. A negative correlation between expression of miR-21 and PTEN was established in vivo. Cell proliferation and chemoresistance to doxorubicin were promoted by overexpression of miR-21 in T24 cells. BCL-2 up-regulation could be achieved by miR-21 overexpression, which prevented T24 cells from apoptosis induced by doxorubicin. Furthermore, the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002. These data verified the oncogenic role of miR-21 in TCCs and may usher in new therapeutic strategies in treating this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468550     DOI: 10.3892/or.2011.1245

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  38 in total

1.  RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation.

Authors:  Baisong Liao; Yan Hu; Gary Brewer
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

2.  A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis.

Authors:  Xiao Yang; Yidong Cheng; Pengchao Li; Jun Tao; Xiaheng Deng; Xiaolei Zhang; Min Gu; Qiang Lu; Changjun Yin
Journal:  Tumour Biol       Date:  2014-09-30

3.  miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.

Authors:  Shibing Guo; Rui Bai; Wanlin Liu; Aiqing Zhao; Zhenqun Zhao; Yuxin Wang; Yong Wang; Wei Zhao; Wenxuan Wang
Journal:  Tumour Biol       Date:  2014-04-22

4.  Regulation of growth of human bladder cancer by miR-192.

Authors:  Yongchao Jin; Jiasun Lu; Jiling Wen; Yinzhou Shen; Xiaofei Wen
Journal:  Tumour Biol       Date:  2015-01-09

5.  Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis.

Authors:  Laura Giunti; Martina da Ros; Serena Vinci; Stefania Gelmini; Anna Lisa Iorio; Anna Maria Buccoliero; Stefania Cardellicchio; Francesca Castiglione; Lorenzo Genitori; Maurizio de Martino; Sabrina Giglio; Maurizio Genuardi; Iacopo Sardi
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy.

Authors:  Xuefeng Li; Sijia Wang; Yan Chen; Guifeng Liu; Xiaoyu Yang
Journal:  Tumour Biol       Date:  2014-03-09

7.  MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS.

Authors:  Yi Xiao; Taoran Deng; Changliang Su; Zhen Shang
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

8.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

9.  Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

Review 10.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Yajaira Suárez
Journal:  Pharmacol Res       Date:  2013-04-18       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.